LONDON, Jan. 9, 2017 /PRNewswire/ -- The liquid biopsy market is expected to reach USD 1.66 billion by 2021 from USD 0.58 billion in 2016, growing at a CAGR of 23.4% during the forecast period of 2016 to 2021. Liquid biopsy is a non-invasive alternative to invasive solid tumor biopsies; it detects biomarkers from primary tumors and from metastatic sites to ascertain genetic information about tumors.
This report segments the liquid biopsy market on the basis of cancer type, circulating biomarkers, end users, products & services, and regions.
Based on cancer type, the market is segmented into lung cancer, breast cancer, colorectal cancer, prostate cancer, liver cancer, and other cancers (melanoma, bladder cancer, and ovarian cancer). Based on circulating biomarkers, the liquid biopsy market is segmented into circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), extracellular vesicles (EVs), and other biomarkers (circulating RNA and protein). The circulating tumor cells segment is expected to account for the largest share of the global liquid biopsy market in 2016, followed by the circulating tumor DNA segment.
Based on end user, the liquid biopsy market is classified into hospital/physician laboratories, reference laboratories, academic and research centers and other end users. The other end-users segment includes public health laboratories, pathology laboratories, and small molecular laboratories. Similarly, based on products and services, the liquid biopsy market is segmented into instruments, reagents, and services and software.
A number of factors, such as technological advancements, increasing number of new cancer cases, benefits of liquid biopsy over solid tumor biopsy, availability of funding, and growing awareness about liquid biopsy through conferences and government initiatives are driving the growth of the liquid biopsy market. However, the unclear regulatory and reimbursement scenario is one of the major factors restraining the growth of this market.
Biocept Inc. (U.S.), Myriad Genetics (U.S.), QIAGEN (Netherlands), Roche (Switzerland), Bio-Rad Laboratories Inc. (U.S.), Trovagene Inc. (U.S.), Guardant Health, Inc. (U.S.), Janssen Diagnostics, LLC (U.S.), Fraunhofer-Gesellschaft (Germany), and MDxHealth SA (U.S.) are the major players in the liquid biopsy market.
Reasons to buy this report:
From an insight perspective, this research report focuses on various levels of analysis—industry analysis (industry trends) and company profiles, which together comprise and discuss the basic views on the competitive landscape; emerging and high-growth segments of the liquid biopsy market; high-growth regions; and market drivers, restraints, and opportunities.
The report provides insights on the following pointers:
- Market Penetration: Comprehensive information on products offered by the top players in the global liquid biopsy market
- Product Development/Innovation: Detailed insights on the upcoming technologies, research & development activities, and new product launches in the liquid biopsy market
- Market Development: Comprehensive information about lucrative emerging markets—the report analyzes the markets for liquid biopsy across various regions
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the global liquid biopsy market
- Competitive Assessment: In-depth assessment of market shares, strategies, products, and manufacturing capabilities of the leading players in the liquid biopsy market
Download the full report: https://www.reportbuyer.com/product/4007885/
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/liquid-biopsy-market-by-cancer-type-circulating-biomarkers-product-end-user---forecast-to-2021-300387718.html